Symbols

PMCB

PharmaCyte Biotech·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Stock Price Surged Significantly

Ample Liquidity

Gap Up

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PMCB

Pharmacyte Biotech, Inc.

A clinical-stage biotech company that developing therapies for cancer and diabetes

Industry

Biological Technology

Established Date

Listing Date

08/10/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

04-30

Website

www.pharmacyte.com

Security Type

Common stock

Office address

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169

Business

Introduction

PharmaCyte Biotech, Inc., is a Nevada company founded in 1996. The Company is a biotechnology company focused on developing and preparing to commercialize cell therapies for cancer, diabetes and malignant ascites based on proprietary cellulose-based living cell encapsulation technology, referred to as Cell-in-a-Box. The company is working to advance clinical research and development of new cell-based therapies for oncology and diabetes. The group has been working to complete the list of items required by the FDA. The company is also developing a method to delay the production and accumulation of malignant ascites caused by various types of abdominal cancerous tumors. The company's treatment for malignant ascites involves using the same envelope cells used for pancreatic cancer, but placing the envelope cells in the patient's abdominal cavity and injecting ifosfamide intravenously. In addition to these cancer projects, the company is also considering how to use the benefits of Cell-in-a-Box technology to develop cancer therapies, including precursors based on certain components of the cannabis plant.

Company Financials

EPS

PMCB has released its 2024 Q2 earnings. EPS was reported at -0.26, versus the expected 0, missing expectations. The chart below visualizes how PMCB has performed over recent quarters, highlighting trends in earnings surprises.